DK1255559T3 - Anvendelse af inhibitorer af caspase-3 eller den caspaseaktiverede desoxyribonuclease (CAD) til behandlingen af hjertesygdomme - Google Patents

Anvendelse af inhibitorer af caspase-3 eller den caspaseaktiverede desoxyribonuclease (CAD) til behandlingen af hjertesygdomme

Info

Publication number
DK1255559T3
DK1255559T3 DK01913667T DK01913667T DK1255559T3 DK 1255559 T3 DK1255559 T3 DK 1255559T3 DK 01913667 T DK01913667 T DK 01913667T DK 01913667 T DK01913667 T DK 01913667T DK 1255559 T3 DK1255559 T3 DK 1255559T3
Authority
DK
Denmark
Prior art keywords
caspase
cad
inhibitor
inhibitors
treatment
Prior art date
Application number
DK01913667T
Other languages
English (en)
Inventor
Karl-Ludwig Laugwitz
Alessandra Moretti
Martin Ungerer
Original Assignee
Procorde Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procorde Gmbh filed Critical Procorde Gmbh
Application granted granted Critical
Publication of DK1255559T3 publication Critical patent/DK1255559T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK01913667T 2000-02-16 2001-02-16 Anvendelse af inhibitorer af caspase-3 eller den caspaseaktiverede desoxyribonuclease (CAD) til behandlingen af hjertesygdomme DK1255559T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10006889A DE10006889A1 (de) 2000-02-16 2000-02-16 Verwendung von Inhibitoren von Caspase-3 oder der Caspase-aktivierten Desoxyribonuclease (CAD) zur Behandlung von Herzerkrankungen
PCT/DE2001/000616 WO2001060400A2 (de) 2000-02-16 2001-02-16 Verwendung von inhibitoren von caspase-3 oder der caspase-aktivierten desoxyribonuclease (cad) zur behandlung von herzerkrankungen

Publications (1)

Publication Number Publication Date
DK1255559T3 true DK1255559T3 (da) 2004-06-01

Family

ID=7631089

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01913667T DK1255559T3 (da) 2000-02-16 2001-02-16 Anvendelse af inhibitorer af caspase-3 eller den caspaseaktiverede desoxyribonuclease (CAD) til behandlingen af hjertesygdomme

Country Status (9)

Country Link
US (1) US20030130216A1 (da)
EP (1) EP1255559B1 (da)
JP (1) JP2003522801A (da)
AT (1) ATE265227T1 (da)
AU (1) AU2001239183A1 (da)
DE (2) DE10006889A1 (da)
DK (1) DK1255559T3 (da)
ES (1) ES2220736T3 (da)
WO (1) WO2001060400A2 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7160859B2 (en) * 2002-10-11 2007-01-09 University Of Medicine & Dentistry Of New Jersey Mst1 modulation of apoptosis in cardiac tissue and modulators of Mst1 for treatment and prevention of cardiac disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11504209A (ja) * 1995-04-21 1999-04-20 メルク エンド カンパニー インコーポレーテッド アポパイン
WO1999010501A1 (en) * 1997-08-22 1999-03-04 Chiron Corporation Apoptosis-associated nuclease cpan
KR100580333B1 (ko) * 1997-10-10 2006-05-16 시토비아 인크. 디펩티드 고사 억제제 및 그의 용도
JPH11239495A (ja) * 1997-12-25 1999-09-07 Osaka Bio Science Kenkyusho カスパ―ゼ活性化ｄｎア―ゼの阻害物質
WO1999047154A1 (en) * 1998-03-16 1999-09-23 Cytovia, Inc. Dipeptide caspase inhibitors and the use thereof
WO1999054482A1 (en) * 1998-04-16 1999-10-28 Board Of Regents, The University Of Texas System Dna fragmentation factor involved in apoptosis

Also Published As

Publication number Publication date
US20030130216A1 (en) 2003-07-10
ATE265227T1 (de) 2004-05-15
DE10006889A1 (de) 2001-09-06
AU2001239183A1 (en) 2001-08-27
JP2003522801A (ja) 2003-07-29
EP1255559A2 (de) 2002-11-13
WO2001060400A3 (de) 2002-04-18
WO2001060400B1 (de) 2002-07-18
EP1255559B1 (de) 2004-04-28
WO2001060400A2 (de) 2001-08-23
ES2220736T3 (es) 2004-12-16
DE50102129D1 (de) 2004-06-03

Similar Documents

Publication Publication Date Title
ATE422357T1 (de) Verwendung von allopurinol zur behandlung von bluthochdruck
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
BR0209365A (pt) Usos farmacêuticos de bisfosfonatos
BR9806752A (pt) Ftalazinonas.
ES2097208T3 (es) Composiciones y procedimientos terapeuticos y sinergicos.
BRPI0213786B8 (pt) peptídeos efetivos no tratamento de tumores e outras condições que requerem a remoção ou destruição de células
BG107157A (en) Sustained release beadlets containing stavudine
ES2173923T3 (es) Procedimiento que permite inactivar un virus en presencia de un polieter y de un agente.
DE59510466D1 (de) Lebendvakzine zur behandlung von tumorerkrankungen
DE60218843D1 (de) Verfahren zur identifizierung von mitteln zur behandlung von diabetes
DE50010519D1 (de) Pharmazeutische Zusammensetzungen zur Therapie der Herzinsuffizienz
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
DK1255559T3 (da) Anvendelse af inhibitorer af caspase-3 eller den caspaseaktiverede desoxyribonuclease (CAD) til behandlingen af hjertesygdomme
EA200501549A1 (ru) Применение экспрессирующего вектора, кодирующего ингибитор il-18, для лечения и/или профилактики заболевания сердца и способ лечения заболевания сердца
ATE347606T1 (de) Gentherapie für kongestives herzversagen
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
DE602005006809D1 (de) Behandlung von nicht-alkoholischer steatotischer hepatitis (nash)
BR0014667A (pt) Prevenção e tratamento de doenças relacionadas à coagulação sanguìnea
BR0209145A (pt) Vacina contra varìola
NO20033541L (no) Anvendelse av fosfodiesteraseinhibitorer av type 4 ved hjertemuskelsykdommer
Wedgwood et al. Combined superoxide dismutase/catalase mimetics alter fetal pulmonary arterial smooth muscle cell growth
NO986041L (no) FremgangsmÕte ved behandling av plantesykdom
WO2003016343A3 (en) USE OF αCP1, αCP2, AND HUR FOR MODULATING GENE EXPRESSION AND INDUCING ANGIOGENESIS
ATE210990T1 (de) Therapeutischer viraler wirkstoff, welcher das fortschreiten von tumoren stoppt
WO2001096398A3 (en) Uncoupling proteins as targets for the treatment of heart failure